Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 263-272

  Oates, Jim C ^a,b   Shaftman, Stephanie R ^a   Self, Sally E ^a   Gilkeson, Gary S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; CREATININE; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY INJURY; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MULTIVARIATE ANALYSIS; NITRATES; NITRITES; SEVERITY OF ILLNESS INDEX;

EID: 38149094981     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23153     Document Type: Article

References (46)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 87-96.
2. Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol 2006;121:243-50.
3. Njoku CJ, Patrick KS, Ruiz P Jr, Oates JC. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J Investig Med 2005;53:347-52.
4. Wigand R, Meyer J, Busse R, Hecker M. Increased serum NG-hydroxy-L-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann Rheum Dis 1997;56:330-2.
5. Gonzalez-Crespo MR, Navarro JA, Arenas J, Martin-Mola E, de la Cruz J, Gomez-Reino JJ. Prospective study of serum and urinary nitrate levels in patients with systemic lupus erythematosus. Br J Rheumatol 1998;37:972-7.
6. Furusu A, Miyazaki M, Abe K, Tsukasaki S, Shioshita K, Sasaki O, et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int 1998;53:1760-8.
7. Wang JS, Tseng HH, Shih DF, Jou HS, Ger LP. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997;77:404-11.
8. Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 2001;44:1203-8.
9. 2+ signaling profile of lupus T cells. J Immunol 2004;173:3676-83.
10. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999;26:318-24.
11. Rolla G, Brussino L, Bertero MT, Colagrande P, Converso M, Bucca C, et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol 1997;24:1066-71.
12. Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
13. Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol 2002;130:345-51.
14. Ho CY, Wong CK, Li EK, Tam LS, Lam CW. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:117-22.
15. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
16. Jungersten L, Edlund A, Petersson AS, Wennmalm A. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol 1996;16:369-79.
17. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999;42:1354-60.
18. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular diseases. 1st ed. Tokyo: Igaku-Shoin; 1982.
19. Austin HA III, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983;75:382-91.
20. Food and Drug Administration. Systemic lupus erythematosus concept paper. Transcript of the Arthritis Advisory Committee Meeting; 2003 Sep 29; Bethesda, MD. URL: www.fda.gov/ohrms/dockets/ac/03/transcripts/3984T1.DOC.
21. Kunz D, Walker G, Eberhardt W, Pfcilschifter J. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1β-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A 1996;93:255-9.
22. Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002;11:411-8.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
24. Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994;179:651-60.
25. Reilly CM, Farrelly LW, Viti D, Redmond ST, Hutchison F, Ruiz P, et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 2002;61:839-46.
26. Dooley MA, Hogan S, Jennette C, Falk R, for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
27. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians 1999;111:611-21.
28. Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, et al. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J Rheumatol 2003;30:60-7.
29. Xu W, Humphries S, Tomita M, Okuyama T, Matsuki M, Burgner D, et al. Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: assessment of the NOS2A gene and predisposition to infectious disease. Nitric Oxide 2000;4:379-83.
30. Levesque MC, Hobbs MR, Anstey NM, Vaughn TN, Chancellor JA, Pole A, et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria [published erratum appears in J Infect Dis 2000;181:408]. J Infect Dis 1999;180:1994-2002.
31. Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, et al. Nitric oxide synthase 2 (G-954C), increased nitric oxide production, and protection against malaria. J Infect Dis 2001;184:330-6.
32. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, and Members of the British Isles Lupus Assessment Group (BILAG). Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. QJM 1988;69:927-37.
33. Lincoln J, Hoyle CH, Burnstock G. Nitric oxide in health and disease. New York: Cambridge University Press; 1997.
34. Mosley K, Waddington SN, Ebrahim H, Cook T, Cattell V. Inducible nitric oxide synthase induction in Thy 1 glomerulonephritis is complement and reactive oxygen species dependent. Exp Nephrol 1999;7:26-34.
35. Montalto MC, Hart ML, Jordan JE, Wada K, Stahl GL. Role for complement in mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression. Am J Physiol Gastrointest Liver Physiol 2003;285:G197-206.
36. Boyd CS, Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol Chem 2002;383:411-23.
37. Zheng L, Sinniah R, I-Hong Hsu S. Renal cell apoptosis and proliferation may be linked to nuclear factor-κB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 2006;37:637-47.
38. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103:3677-83.
39. Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-κB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic Biol Med 1999;27:752-63.
40. Raats CJ, van den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000;57:385-400.
41. Schildknecht S, Bachschmid M, Ullrich V. Peroxynitrite provides the peroxide tone for PGHS-2-dependent prostacyclin synthesis in vascular smooth muscle cells. FASEB J 2005;19:1169-71.
42. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 1997;378:707-13.
43. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002;109:817-26.
44. Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med 2004;36:233-47.
45. Piganelli JD, Flores SC, Cruz C, Koepp J, Batinic-Haberle I, Crapo J, et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002;51:347-55.
46. Habib S, Moinuddin AR. Peroxynitrite-modified DNA: a better antigen for systemic lupus erythematosus anti-DNA autoantibodies. Biotechnol Appl Biochem 2006;43:65-70.